Haoxi Health Technology Ltd HAO
Advertising · IPO 2024 · data as of November 13, 2026
Haoxi Health Technology Ltd (HAO) is a consumer discretionary company listed in the US with a market value of about $1M. In fiscal year 2026 it had revenue of $55M and net income of -$10M, a net margin of -17.4%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is track record (0/5).
Key numbers: a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 8045% above the current price.
About Haoxi Health Technology
Haoxi Health Technology is listed in the US and classified in advertising, IPO year 2024. Revenue went from $16M in 2022 to $55M in 2026, growth of about 35.7% a year. It was profitable in 4 of the last 5 years in our data. It spends 0% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $55M | $33M | $49M | $28M | $16M |
| Net income | -$10M | $4M | $1M | $969752 | $244587 |
| Free cash flow | — | — | -$802943 | -$917632 | -$684059 |
| EPS (diluted) | $-14.96 | $6.08 | $2.03 | $1.52 | $0.38 |
| Net margin | -17.4% | 11.8% | 2.7% | 3.4% | 1.5% |
| ROIC | -42.1% | -10.3% | 10.3% | 50.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Haoxi Health Technology stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 8045% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Haoxi Health Technology pay a dividend?
Not currently.
Is Haoxi Health Technology a good stock to buy?
We do not give buy or sell advice. Haoxi Health Technology scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.